See our exclusive index of companies on the move:
Explore Stocks- Top Stocks
- Top Australian Gold Stocks
- Top ASX Copper Stocks
- Top ASX Nickel Stocks
- Top ASX Rare Earth Stocks
- Top Battery Metals Stocks on the ASX
- Top Australian Lithium Stocks
- Top Graphite Miners on the ASX
- 10 ASX Cannabis Stocks
- Top ASX Tech Stocks
- Top AI Stocks on the ASX
- On Site
- About Australian Cannabis Investing
- About Australian Resource Investing
- About Australian Tech Investing
- About Australia Investing
- Of Interest
- ASEAN-Australia-New Zealand Trade Agreement
- Association of Southeast Asian Nations (ASEAN)
- Australian FAQ on ASEAN
- Australia Government on Foreign Investments
MGC Pharma Receives First Government Grant for Clinical Trial
MGC Pharma announced it’s received government funding for its clinical trial with the University of Notre Dame Western Australia.
MGC Pharmaceuticals (ASX:MXC) announced on Tuesday (November 12) it’s received funding from the Australian Commonwealth Government for its clinical trial in collaboration with the University of Notre Dame Western Australia.
As quoted in the press release:
Key Highlights:
First AU$25,000 of the AU$50,000 Grant received
The Grant supports the CogniCann® Phase IIb clinical trial being conducted in collaboration with the University of Notre Dame Western Australia
Securing the Grant demonstrates the Australian Governments’ support for the Company’s stated growing Research & Development agenda, alongside broader continued research into the therapeutic use of phytocannabinoids
The Phase IIb double-blind placebo controlled clinical trial is assessing symptoms associated with dementia and Alzheimer’s disease
Top News
FEATURED STOCKS
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.